Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345455 | 0.81 | GOT1 (0.38) | GOT1P2RX7CYP1A2CYP11B2 | |
| SCHEMBL329940 | 0.79 | GOT1 (0.37) | GOT1P2RX7CYP1A2CYP11B2 | |
| SCHEMBL5407665 | 0.77 | NAPRT (0.42) | GOT1P2RX7CYP1A2CYP11B2PER2 | |
| SCHEMBL1076498 | 0.77 | GOT1 (0.40) | GOT1P2RX7CYP1A2 | |
| SCHEMBL1640109 | 0.77 | GOT1 (0.35) | GOT1P2RX7CYP1A2CYP11B2PER2 | |
| SCHEMBL25213053 | 0.77 | ALDH1A1 (0.41) | GOT1P2RX7CYP1A2CYP11B2 | |
| SCHEMBL31005932 | 0.77 | GOT1 (0.35) | GOT1P2RX7CYP1A2CYP11B2PER2 | |
| SCHEMBL29892805 | 0.77 | NAPRT (0.42) | GOT1P2RX7CYP1A2CYP11B2PER2 | |
| SCHEMBL29892579 | 0.76 | NAPRT (0.41) | GOT1P2RX7CYP1A2 | |
| Hydrochloric Acid SCHEMBL28110023 | 0.76 | NAPRT (0.41) | GOT1P2RX7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-03-20 | — | — | US | disclosed |
| CN-118715217-A | Piperazine indole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12098144-B2 | Piperazine indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-22 | — | — | US | disclosed |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-22 | — | — | US | disclosed |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-22 | — | — | US | disclosed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1491541-B1 | Pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1491540-B1 | Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2006-12-13 | — | — | EP | disclosed |
| CN-1215067-C | Pyridazinone aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1500087-A | Pyridazinone aldose reductase inhibitors | �Ʒ� | 2004-05-26 | — | — | CN | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1373259-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | disclosed |
| US-20030114357-A1 | Antidiabetic agents | FRYBURG DAVID A (US) | 2003-06-19 | — | — | US | disclosed |
| US-6579879-B2 | Pyridazinone aldose reductase inhibitors | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| EP-1298223-A2 | Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene | Pfizer Products Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | GOT1 828/4885P2RX7 821/4885CYP1A2 1208/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | GOT1 995/4885P2RX7 1397/4885CYP1A2 1417/4885 |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | GOT1 2389/4885P2RX7 260/4885CYP1A2 206/4885 |
| US-12098144-B2 | Piperazine indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR5A2 | GOT1 2742/4885P2RX7 298/4885CYP1A2 142/4885 |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | GOT1 2389/4885P2RX7 260/4885CYP1A2 206/4885 |
| US-20030114357-A1 | Antidiabetic agents | AKR1B1, AKR1C2, AKR1C1 | GOT1 77/4885P2RX7 4545/4885CYP1A2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.